Clinical trial · Observational
Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy
NCT01198301CI-TRIAL-00018619completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators want to develop a gene expression profile the for prediction the chemotherapeutic response of patients with metastatic breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasm Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Chemotherapy response
- timeFrame
- four-months
- description
- Response to chemotherapy is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines
Secondary outcomes (3)
- measure
- Time to disease progression
- timeFrame
- six months
- description
- Time to disease progression is measured from the date therapy is initiated to the date of documented disease progression.
- measure
- Overall survival
- timeFrame
- one year
- description
- Overall survival is measured from the date therapy is initiated to the date of death or final follow-up.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients should be histologically confirmed with metastatic breast cancer; * Patients who had completed the planned chemotherapy regimen with no major protocol violation; * an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; * At least one measurable lesion; * Normal cardiac, hepatic, renal and bone marrow functions; * Life expectancy ≥3 months; * Discontinuity of previous chemotherapy for a minimum of 4 weeks. Exclusion Criteria: * previous history of other malignancies; * previous surgery history on the needle biopsy organ; * Central nervous system metastases; * Serious or uncontrolled concurrent medical illness.
References
Publications (0)
Data not yet available
No reference posted for this study.